3:40 PM
 | 
Feb 02, 2018
 |  BC Extra  |  Company News

Intarcia terminates Phase III diabetes trials

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials earlier this week evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov. The company received a complete response letter from FDA in September for an NDA seeking approval in...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >